Ken Griffin Morphic Holding, Inc. Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	BUY	$26.12 - $34.07 $195,900 - $255,525	7,500 Added 35.21%	28,800 $981,000
Q1 2024 May 15, 2024	BUY	$26.64 - $40.31 $471,528 - $713,487	17,700 Added 491.67%	21,300 $749,000
Q4 2023 Feb 14, 2024	SELL	$19.95 - $31.0 $101,745 - $158,100	-5,100 Reduced 58.62%	3,600 $103,000
Q3 2023 Nov 14, 2023	SELL	$21.33 - $59.42 $6,398 - $17,826	-300 Reduced 3.33%	8,700 $199,000
Q2 2023 Aug 14, 2023	BUY	$34.33 - $62.11 $264,341 - $478,247	7,700 Added 592.31%	9,000 $515,000
Q1 2023 May 15, 2023	BUY	$26.01 - $48.69 $28,611 - $53,559	1,100 Added 550.0%	1,300 $48,000
Q4 2022 Feb 14, 2023	BUY	$24.14 - $30.37 $4,828 - $6,074	200 New	200 $5,000

140

38.7M

4.2K

200K

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.